Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

The UFS issues a statement regarding the outcome of recent court case
2014-09-15

A significant number of reports appeared in the media the past week regarding this alleged attack, which happened on the Bloemfontein Campus of the UFS on 17 February 2014.

Although the senior leadership of the UFS is always in favour of good and objective journalism, we find it unfortunate that some of the facts are reported in a misleading and/or inaccurate way by some of the local media.

It is important to us that the true facts are stated. Not only for the sake of those involved, but also for our staff, students, alumni and other important stakeholders.

Here are the facts:

1.    The university was not the complainant. The alleged incident was reported to the South African Police Service (SAPS) by the victim, Muzi Gwebu, and the charges were laid by the State.

2.    At no point did the university management in any of its public statements describe this incident as a case of racism; not once. Charges of racism, then and now, must be proven, not assumed to be true simply because someone alleges racism. That is our standard approach, then and now.

3.    Cobus Muller and Charl Blom were suspended by the university, not expelled – pending the results of the court case. Emotions were running high among members of the student body and, on grounds of the evidence available to the university management at the time, as well as concerns for student and campus safety, they were suspended pending the outcome of a court hearing. This is normal procedure. Suspension does not mean you are guilty; it means you have a case to answer, either according to the university's disciplinary procedures or in the courts. For these reasons the university management will not apologise for the suspension.

4.    The university awaited the outcome of the court case before deciding whether disciplinary action should also be taken against Cobus Muller and Charl Blom. In the light of both the South African Human Rights Commission (SAHRC) and the Regional Court rulings, the university management subsequently decided to lift the suspensions of both Muller and Blom from all campuses of the university with immediate effect.

Muzi Gwebu laid serious charges with the SAPS almost immediately after the incident, and the university management believed, on the evidence then available, that the students had a case to answer.
 
5.    As the Director of Public Prosecutions decides on who will be prosecuted and who not, there are no grounds for the university to pay the legal fees of any of the students in this case.
 
Finally:
The University of the Free State will not be fazed by inaccurate and distorted information, rumour and exaggerations. We are still striving to become a truly excellent university, with a focus on the academic, but also the human development of our students.

Issued by: Lacea Loader (Director: Communication and Brand Management)
Tel: +27 (0) 51 401 2584 | +27 (0) 83 645 2454
E-mail: news@ufs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept